Home Dompé Announces The EMA Has Granted Orphan Drug Designation To Its rhNGF-Based Treatment For Retinitis Pigmentosa
 

Keywords :   


Dompé Announces The EMA Has Granted Orphan Drug Designation To Its rhNGF-Based Treatment For Retinitis Pigmentosa

2013-07-01 09:05:00| drugdiscoveryonline News Articles

Dompé, a leading company in research & development of novel treatment solutions for rare diseases, announces its investigational drug based on the recombinant human nerve growth factor (rhNGF) for the treatment of retinitis pigmentosa (RP) has been granted orphan drug designation

Tags: treatment drug granted announces

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
23.11PlayStationVitaPCH-2000
23.11GB
23.11 Malbon
23.11PING PEARL GATES
23.11WATCH
23.11L
23.11Tetsuya_SP2 DMC
23.116
More »